The Obama administration recently called on the public for ideas to streamline federal regulations. In response, the National Association of Chain Drug Stores has sent its suggestion to the Food and Drug Administration.
A new study indicated that two insulin products made by French drug maker Sanofi lower blood-glucose levels to a greater extent than premixed insulin, and with improvements in quality of life and less hypoglycemia.
Novo Nordisk unveiled data from two extension studies at the 71st annual Scientific Sessions of the American Diabetes Association in San Diego that show its diabetes drug, when combined with other medications, may help patients achieve blood-sugar control.
An insulin product made by Eli Lilly appears likely to be more cost-effective than long-acting insulin analog, according to a study presented Friday at the American Diabetes Association’s 71st Scientific Sessions in San Diego.
The law targeting data mining in Vermont, along with laws in New Hampshire and Maine, would have forced drug companies to significantly change the way they market drugs to physicians had the Supreme Court allowed them to stand in the case of Sorrell, Attorney General of Vermont, et al. vs. IMS Health Inc., et al.
Looking to appeal to boys and young men with its innovative product design is Stinky Boyz, a line of all-natural personal hygiene products that are shaped like sports balls. Stinky Boyz hygiene products contain essential oils and black seed, a strong antioxidant that helps cleanse the body of toxins.
A recent study published in Panminerva Medica found that a pycnogenol and coenzyme-Q10 combination (PycnoQ10) taken by stable heart failure patients as an adjunct to medical treatment naturally strengthens the heart, increasing the blood volume ejected with each beat.
Patients with inflammatory conditions may have lower rates of diabetes if they take drugs commonly used to treat arthritis, according to a new study published in the Journal of the American Medical Association.
It seems that intensive-dose statin therapy is linked with a higher risk of onset diabetes, compared with moderate-dose therapy, according to an analysis published in the Journal of the American Medical Association.